Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 13/20 | 0.70 |
| ▸ | PPARG | P37231 | 4/20 | 0.66 |
| ▸ | PPARA | Q07869 | 4/20 | 0.66 |
| ▸ | PPARD | Q03181 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566373 | 1.00 | ACE (0.70) | ACEPPARGPPARAPPARDGAA | |
| SCHEMBL4459598 | 0.88 | ACE (0.56) | ACEPPARGPPARAGAA | |
| SCHEMBL1632958 | 0.86 | ACE (0.66) | ACEPPARGPPARAPPARDGAA | |
| SCHEMBL16097891 | 0.85 | ACE (0.53) | ACEPPARGPPARA | |
| SCHEMBL1278177 | 0.85 | PPARA (0.89) | ACEPPARGPPARAPPARD | |
| SCHEMBL28344059 | 0.85 | ACE (0.68) | ACEPPARGPPARAPPARD | |
| SCHEMBL1278179 | 0.85 | PPARA (0.89) | ACEPPARGPPARAPPARD | |
| SCHEMBL11331399 | 0.85 | PPARA (0.89) | ACEPPARGPPARAPPARD | |
| SCHEMBL28344061 | 0.85 | ACE (0.68) | ACEPPARGPPARAPPARD | |
| SCHEMBL13870212 | 0.85 | ACE (0.68) | ACEPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464784-B2 | Inhibition of aminocylase 3 (AA3) in the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-11 | — | — | US | disclosed |
| US-20200206239-A1 | INHIBITION OF AMINOCYLASE 3 (AA3) IN THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-02 | — | — | US | disclosed |
| WO-2019055825-A1 | INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2009151744-A1 | S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES | GALLEON PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206239-A1 | INHIBITION OF AMINOCYLASE 3 (AA3) IN THE TREATMENT OF CANCER | PLAAT3, HCCS, LAP3 | ACE 836/4885PPARG 1762/4885PPARA 1777/4885 |
| US-11464784-B2 | Inhibition of aminocylase 3 (AA3) in the treatment of cancer | PLAAT3, HCCS, LAP3 | ACE 836/4885PPARG 1762/4885PPARA 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.